Melt Pharmaceuticals, Inc. filed for an initial public offering with the Securities and Exchange Commission on Wednesday.
The company said it is focused on developing and commercializing “proprietary non-opioid, non-IV, sedation and anesthesia therapeutics for human medical procedures.”
It also said “the core intellectual property we own is a patented series of combination non-opioid sedation drug formulations that we believe have multiple clinical applications for potential indications of use.”
Harrow Health, Inc. and Opaleye, L.P. are listed among the company’s principal stockholders.
Melt Pharmaceuticals said it applied to list on the Nasdaq Capital Market under the symbol MELT.
The company didn’t give an expected size for its IPO, nor did it provide an anticipated price range.
Aegis Capital Corp. is listed as the offering’s underwriter.
